SectorPharmaceutical
Established Date29/03/2021
Listing Date25/06/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees73
Fiscal Year Ends31/12
Security TypeCommon stock
Office addressJoshua Dawson House, Dawson Street, Dublin 2, D02 RY95, Ireland
Business
IntroductionGH Research PLC was incorporated under the laws of Ireland on 29 March 2021. The company is a clinical-stage biopharmaceutical company dedicated to transforming patients' lives by developing a treatment that transforms the practice of depression. The company's initial focus is on the development of new and proprietary mebufostin therapies for the treatment of patients with treatment-resistant depression (TRD). Their product portfolio currently includes GH001, a proprietary inhalable mebufostin product candidate, and GH002, a proprietary intravenous mebufostin product candidate.
